tirzepatide bmi New drug delivers significant and long-lasting weight loss Effect of tirzepatide in SURMOUNT-1

And its not something you can manufacture by willpower alone. The clinicians we spoke with unanimously agree that GLP-1s generally should be taken for life

Yes, your skincare expires Here's how to tell when it's time to let go We hate to be the bearer of bad news, but that half-used cream tucked in the back of your cabinet

What's New: August 2026 Update TRIUMPH-2 CONFIRMED (July 23, 2026): Obesity + type 2 diabetes trial, 1,152 patients up to 20.8% weight loss (12mg) and up to -1.6 percentage points HbA1c reduction at 80 weeks TRIUMPH-3 CONFIRMED (July 23, 2026): Obesity + established cardiovascular disease trial, 1,949 patients up to 22.6% weight loss (12mg) at 80 weeks, plus significant improvements in triglycerides, blood pressure, and inflammatory markers All four core TRIUMPH registrational trials are now complete TRIUMPH-4, TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 have all reported positive topline results TRIUMPH-1 reminder: 45.3% of patients on 12mg lost 30% of body weight, and a 104-week extension in patients with BMI 35 reached up to 30.3% average weight loss surgical-level outcomes that remain the strongest efficacy data in the program Filing type confirmed: BLA, not NDA Eli Lilly will submit a Biologics License Application (retatrutide is regulated as a biologic), now expected Q1 2027 (shifted from the previously estimated Q4 2026) Lilly's own statement: "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea" TRIUMPH-Outcomes (cardiovascular and kidney outcomes, ~10,000 patients) remains separate and ongoing not expected until 20282029, and not required for initial approval Current Status: Where Things Stand Retatrutide is an investigational medication developed by Eli Lilly

published a comprehensive review on the use of GLP-1 RAs in plastic surgery, focusing for the first time primarily on their potential benefits and practical considerations in reconstructive procedures [96]

Convenience also posits its own argument